Literature DB >> 27987035

Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection.

Ryuta Saito1, Toshihiro Kumabe2, Masayuki Kanamori2, Yukihiko Sonoda2, Teiji Tominaga2.   

Abstract

The indications of surgery for thalamic high-grade gliomas are not well established. The present study investigated the outcome of 21 patients treated by surgery and reports the high incidence of distant recurrences including disseminations after successful removal. Twenty-one patients with thalamic high-grade gliomas not invading the pyramidal tract or midbrain underwent cytoreductive surgery at our institute from June 1997 to August 2015. Surgery was performed with the aid of a neuronavigation system, electrophysiological monitoring, and fluorescence navigation. Tumor histology included 12 cases of the World Health Organization grade III and nine cases of grade IV. Gross total resection was achieved in six cases, subtotal in 13, and partial in two. Motor weakness accompanied by sensory disturbance deteriorated immediately after surgery in 13 patients. However, five patients were determined to show deterioration at 2 months after surgery. Postoperative radiation and chemotherapy were given to every patient, and median progression-free survival of patients with grade III and IV tumors was 12.1 and 7.0 months, respectively. Median overall survival of patients with grade III and IV tumors was 25.6 and 12.6 months, respectively. High incidence of distant recurrences was found, with distant lesions at recurrence in 13 of 19 patients with recurrence, suggesting the life-restricting factor in these patients. Thalamic high-grade glioma without invasion into the pyramidal tract and brainstem can be considered as a candidate for surgical resection. Distant lesion limits the survival of patients after successful resection.

Entities:  

Keywords:  Dissemination; High-grade glioma; Morbidity; Surgery; Thalamic glioma

Mesh:

Year:  2016        PMID: 27987035     DOI: 10.1007/s10143-016-0804-x

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  32 in total

1.  Primary tumours of the thalamus.

Authors:  W McKISSOCK; K W PAINE
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

2.  Tumors of the basal ganglia; their surgical treatment.

Authors:  C ARSENI
Journal:  AMA Arch Neurol Psychiatry       Date:  1958-07

3.  Thalamic gliomas: a clinicopathologic analysis of 20 cases with reference to patient age.

Authors:  S Nishio; T Morioka; S Suzuki; I Takeshita; M Fukui
Journal:  Acta Neurochir (Wien)       Date:  1997       Impact factor: 2.216

4.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

5.  Thalamic tumors.

Authors:  W R Cheek; J M Taveras
Journal:  J Neurosurg       Date:  1966-02       Impact factor: 5.115

6.  The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.

Authors:  G E Keles; B Anderson; M S Berger
Journal:  Surg Neurol       Date:  1999-10

7.  Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases.

Authors:  Carla Fernandez; André Maues de Paula; Carole Colin; Benoît Quilichini; Corinne Bouvier-Labit; Nadine Girard; Didier Scavarda; Gabriel Lena; Dominique Figarella-Branger
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

8.  Stereotactic biopsy and resection of thalamic astrocytomas.

Authors:  P J Kelly
Journal:  Neurosurgery       Date:  1989-08       Impact factor: 4.654

9.  Thalamic tumors in children: a reappraisal.

Authors:  Stephanie Puget; Darach W Crimmins; Matthew R Garnett; Jacques Grill; Ricardo Oliveira; Nathalie Boddaert; Alison Wray; Arielle Lelouch-Tubiana; Thomas Roujeau; Federico Di Rocco; Michel Zerah; Christian Sainte-Rose
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

10.  Role of Intraoperative Neurophysiologic Monitoring in the Resection of Thalamic Astrocytomas.

Authors:  Giorgio Carrabba; Giulio Bertani; Filippo Cogiamanian; Gianluca Ardolino; Barbara Zarino; Andrea Di Cristofori; Marco Locatelli; Manuela Caroli; Paolo Rampini
Journal:  World Neurosurg       Date:  2016-06-23       Impact factor: 2.104

View more
  6 in total

Review 1.  Thalamic tumors in children: case series from our institution and literature review.

Authors:  Daniela Renedo; Florencia Ferraro; Agustín Ruiz Johnson; Romina Argañaraz; Sebastian Giovannini; Joaquín Pérez Zabala; Elena Zemma; Beatriz Mantese
Journal:  Childs Nerv Syst       Date:  2020-07-25       Impact factor: 1.475

2.  Incidence of initial spinal metastasis in glioblastoma patients and the importance of spinal screening using MRI.

Authors:  Ichiyo Shibahara; Ryuta Saito; Yoshinari Osada; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Shunji Mugikura; Mika Watanabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

Review 3.  MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.

Authors:  Hideaki Abe; Manabu Natsumeda; Yu Kanemaru; Jun Watanabe; Yoshihiro Tsukamoto; Masayasu Okada; Junichi Yoshimura; Makoto Oishi; Yukihiko Fujii
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-31       Impact factor: 1.742

4.  MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.

Authors:  Hideaki Abe; Manabu Natsumeda; Masayasu Okada; Jun Watanabe; Yoshihiro Tsukamoto; Yu Kanemaru; Junichi Yoshimura; Makoto Oishi; Rintaro Hashizume; Akiyoshi Kakita; Yukihiko Fujii
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

5.  Maximal surgical resection and adjuvant surgical technique to prolong the survival of adult patients with thalamic glioblastoma.

Authors:  Jaejoon Lim; YoungJoon Park; Ju Won Ahn; So Jung Hwang; Hyouksang Kwon; Kyoung Su Sung; Kyunggi Cho
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

6.  H3K27M and TERT promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma.

Authors:  Yoshinari Osada; Ryuta Saito; Ichiyo Shibahara; Keisuke Sasaki; Takuhiro Shoji; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Mika Watanabe; Teiji Tominaga
Journal:  Neurooncol Adv       Date:  2021-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.